BG Medicine Publishes Study On Use Of Galectin-3 In Drug Therapy In HeartFailure NASDAQ (RTTNews.com) - BG Medicine Inc. (BGMD) announced that results from a sub-study of the Controlled Rosuvastatin Multinational Trial in Heart Failure or CORONA trial were published online in the current issue of the European Heart Journal. BG Medicine Announces Fiscal 2012 First Quarter Results BG Medicine, Inc. Announces Availability of Galectin-3 Diagnostic Testing ... BG Medicine Obtains CE Mark and Files 510(k) for Expanded BGM Galectin-3 ... |
